Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06440005 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Name: A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors — clinical trial record (NCT06440005)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorAngiex, Inc.

Started2024-07-22

View on ClinicalTrials.gov ↗

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.

Amendment history 1 change detected by DataLookout

2026-09-10

Primary completion pushed: 2026-09-06 → 2027-03-06

Trial Details

NCT Number	NCT06440005
Lead Sponsor	Angiex, Inc.
Conditions	Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer +3 more
Enrollment	80 participants
Start Date	2024-07-22
Primary Completion	2027-03-06 (estimated)
Study Completion	2027-09-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-09